Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.
about
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infectionAntimicrobial proteins and polypeptides in pulmonary innate defenceConstitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epitheliaExpression of the secretory leukoprotease inhibitor gene in epithelial cellsThe neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infectionAntimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implicationsSecretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potentialMoraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease.Urethral cytokine and immune responses in Chlamydia trachomatis-infected males.Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis.Changes in the vaginal microenvironment with metronidazole treatment for bacterial vaginosis in early pregnancyActivity of abundant antimicrobials of the human airway.RNA-Seq quantification of the human small airway epithelium transcriptomeModulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester.The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation.Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut.α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatmentSystemic and mucosal differences in HIV burden, immune, and therapeutic responsesEffects of bacterial infection on airway antimicrobial peptides and proteins in COPD.Lung infections. 3. Pseudomonas aeruginosa and other related species.Tracheobronchial protease inhibitors, body surface area burns, and mortality in smoke inhalation.Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung.Proteases and cystic fibrosis.Targeted treatment in COPD: a multi-system approach for a multi-system disease.Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases.Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity.SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.Lactoferrin: an alternative view of its role in human biological fluids.Moraxella catarrhalis: from interactions with the host immune system to vaccine development.The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity.A novel locust (Schistocerca gregaria) serine protease inhibitor with a high affinity for neutrophil elastase.Secretory Leukocyte Protease Inhibitor (SLPI) expression downregulates E-cadherin, induces β-catenin re-localisation and triggers apoptosis-related events in breast cancer cells.Target protein interactions of indole-3-carbinol and the highly potent derivative 1-benzyl-I3C with the C-terminal domain of human elastase uncouples cell cycle arrest from apoptotic signaling.The Pseudomonas aeruginosa secretory product pyocyanin inactivates alpha1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease.Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1beta.In vitro transport of active alpha(1)-antitrypsin to the apical surface of epithelia by targeting the polymeric immunoglobulin receptor.
P2860
Q21134079-4CC91D29-5832-4D5A-9803-E7F53F588D48Q24541575-37CC8BAD-59DB-4C07-8227-5577D7642BC0Q24561981-0FD61537-065B-4391-9917-C989A4C20A1BQ24617821-F7D148A4-610F-42E7-A753-266AC53E2851Q24676095-0C9D3B6F-6967-4578-A613-E0B4FEA2895FQ28087327-CDC88D52-344F-4AF8-9FDF-E30BD7D90EF1Q28296240-03826FC9-01B9-47A6-9F6A-DC4BC6E14869Q30884939-667757FD-9927-438E-90F3-90AE455587C8Q33554451-E33A70B8-A128-42EF-88F5-788F77DB5774Q33760369-F8F9FF12-DCA5-4B7F-8CED-940B10F1921EQ33829381-68DBEDBB-5A19-4AC5-948D-BE3D174A3DB0Q33860518-12C16E04-05B3-4598-882D-90242ECAADA2Q34178271-FEB77811-7835-4F58-9453-C7D233BC26D1Q34236026-10A93216-9AF7-4625-A882-AD6B85EAB69FQ34330083-B4EF2B83-BC0C-4D2D-8DEC-C36491B53301Q34348149-EF1F879D-50EB-4E9C-9056-A8A9B8A80F65Q34621649-6F3D4004-A033-4C65-A6EB-9B16EC8E6E9FQ35115856-7340646D-1C90-4575-876F-6E516365FE1CQ35179153-CDE483C8-8F66-4369-A05D-61D48B99FF22Q35190200-2AF54BEB-AAAE-48CC-976A-B74E4376447DQ35484510-E598362F-15ED-4428-BEC5-8F58BED6289CQ35532283-0E71F491-8AD3-4BE9-95AC-6CBF91E8A374Q35565742-4E9F5B01-EF33-44C5-9B4D-F51DAEEEB97BQ36114167-A9770EA2-94EB-4AD0-B9E1-08C30BA1251CQ36720700-4F4F012C-08A0-4FCC-8113-E4CEB73C745BQ36888636-4D64C6C2-D2AB-4C12-AB07-EF3C130C5002Q37131650-9655B05B-0C48-432D-89AD-BF4093AB6D5AQ37340178-21AAF713-AF8C-4BA7-AEC9-FAEC3373AA02Q37364288-6B69D12A-71AE-4638-907C-9E726A3C19EFQ37731798-FE45C5DF-6EDE-459A-B3D0-D44929CAED08Q37936542-4D7476E6-7E1E-4404-95A9-DBF1342ED306Q38007176-95B394E0-C822-45F3-93F6-175132D6DF90Q38041190-296ABA74-DD83-473A-B5C4-68C5F0449A16Q38845999-0F2A682E-D4DA-4389-A4A3-B381A0A27E5FQ38921354-0E2C54FD-1051-417A-BCA1-CA7872FDC1D8Q38974013-9FB49AC2-B954-4AC5-B960-76E4397D0697Q39455690-0ECFD1ED-665A-4168-A379-743223165394Q39510022-FBDEC867-AC6D-49D5-84C4-C491E41E8C55Q40905287-45DD4A01-5627-4359-ACE7-6689F390F093Q40939270-16BEDBE6-AF92-47A8-99AF-2793CC892F8E
P2860
Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.
description
1991 nî lūn-bûn
@nan
1991 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@ast
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@en
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@nl
type
label
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@ast
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@en
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@nl
prefLabel
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@ast
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@en
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@nl
P2093
P2860
P356
P1476
Anti-neutrophil elastase defen ...... etory leukoprotease inhibitor.
@en
P2093
Crystal RG
Hubbard RC
Schnebli HP
Thompson RC
Vogelmeier C
P2860
P304
P356
10.1172/JCI115021
P407
P577
1991-02-01T00:00:00Z